- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00522626
Fetal Neurobehavior in Non-methadone Maintained Women in Substance Abuse Treatment
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This project examines fetal neurobehavior in non-methadone maintained, opioid dependent women. Subjects are outpatients at the Center for Addiction and Pregnancy on the Johns Hopkins Bayview Medical Center campus, who are between the ages of 18 and 40, who have either completed a methadone detoxification prior to 32 weeks gestation and are on no opiate replacement therapy after 32 weeks gestation, or who have never received methadone maintenance, and are free of maternal or known fetal health complications. Women are consented at 32 weeks of gestation. During the four weeks between consent and fetal testing, women will be privately interviewed by project staff and administered the SCLR-90 (Symptom Checklist) ASRS (Adult ADHD Self-Report Scale), and the PSD (Posttraumatic Stress Diagnostic Scale). These tools will be used to detect symptoms in different psychological domains (SCLR-90), ADHD (ASRS) and PTSD (PSD). At 36 weeks of gestation, women undergo fetal monitoring. Maternal demographic data (i.e. substance use history, pregnancy history, methadone dose, other medications) are abstracted from the maternal chart prior to each session. Women are asked a series of questions (the SOWS, or Subjective Opiate Withdrawal Scale and Adjective Questionnaire), via standardized questionnaires used to detect the presence or absence of withdrawal symptomatology prior to each session. Women will undergo two 60 minute fetal monitoring sessions on this day. The timing of the two sessions is such that it will provide two historical control groups. The first session will occur at 9 AM. The second session will occur at 1 P.M. The use of two fetal testing times will alleviate the problem of fetal circadian rhythms which would otherwise confound one or the other groups. The data acquisition is performed using a standard fetal monitoring system (Toitu 325). Data recorded include fetal movements and fetal heart rate. Additional data to be recorded include maternal EKG via 3 electrodes placed on the maternal chest (right mid sub-clavicle, left mid-axillary thorax) and upper left thigh (for ground lead), maternal respirations via a bellows apparatus attached around the maternal chest beneath the breasts, maternal contractions via the same transducer that detects fetal movement and fetal heart rate, and maternal skin conductance, or electrodermal activity via two electrodes with a gelled skin contact area placed on the index and middle fingers of one hand affixed with adhesive collars to limit gel contact to a 1 cm circle, and velcro. This maternal data will be time synchronized and analyzed in conjunction with fetal data. Also planned is the observation of fetal response to externally applied sound (a baby rattle). At the conclusion of the 60 minute session, an additional 6 minute recording will be added, with three sound stimuli at 1 minute intervals. Infants will undergo neurobehavioral testing on day #3 of life. This testing consists of the administration of the NICU Network Neurobehavioral Scale (the NNNS), a standardized 30-minute harmless and painless evaluation of the infant's motor, sensory and neurologic capabilities. The exam evaluates the infant's responses to auditory and visual stimuli, as well as movement, reflexes, signs of stress and consolability. Infants will also undergo an assessment for vagal tone on the first and third days of life. This assessment will involve obtaining 8-10 minutes of resting heart rate via 3 standard infant EKG leads while the infant is in a quiet state. The EKG leads will be connected directly to a Physio-control EKG monitor (R wave Medical Electronics of Florida). This reading is then transmitted to a vagal tone monitor (Delta Biometrics, Inc.) and computer for data storage and off-line analysis. Software will be used to computer heart period and vagal tone measures.
All fetal testing procedures obtained as part of this protocol are experimental; none are used for clinical purposes. Women consenting to participation will continue to receive routine care at CAP. Participants will be removed from the protocol if they should relapse to any licit or illicit substance between the time of consent (32 weeks gestation) and the time of fetal testing (36 weeks gestation).
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21224
- Johns Hopkins Bayview Medical Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Generally healthy women between ages 18 and 40, current clients of the CAP program
- Singleton, uncomplicated pregnancies, dated with routine 16 to 20 week ultrasound (as is part of standard care at CAP)
- Abstinence from licit and illicit substance abuse in the four weeks prior to consent
Exclusion Criteria:
- Complications of pregnancy, including gestational diabetes, polyhydramnios, hypertension, placenta previa or preterm labor
- Significant maternal health problems related to pregnancy, including HIV infection and Type I diabetes
- Significant maternal psychopathology or other pathology that would preclude informed consent (schizophrenia, mental retardation)
- Recent drug use, defined as positive urine toxicology (performed randomly at least weekly in the treatment center), clinical positives (subject appearing intoxicated at the treatment center) or patient report in the four weeks prior to recruitment, or at any time during study participation (i.e. from 28 weeks to 36 weeks gestation)
- Recent alcohol use, by clinical detection, patient report or breathalyzer reading (performed at the treatment center to confirm clinical impression) at any time in the four weeks prior to recruitment, or at any time during study participation
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: Cohorte
- Perspectives temporelles: Éventuel
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
---|---|
Observational
Opioid exposed pregnancies
|
Simultaneous monitoring of maternal and fetal physiology
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Fetal Heart Rate
Délai: 60 minutes
|
Fetal heart rate in beats per minute
|
60 minutes
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Maternal Physiologic Parameters
Délai: 120 minutes
|
120 minutes
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Publications et liens utiles
Publications générales
- Jansson LM, Dipietro J, Elko A. Fetal response to maternal methadone administration. Am J Obstet Gynecol. 2005 Sep;193(3 Pt 1):611-7. doi: 10.1016/j.ajog.2005.02.075.
- Jansson LM, Di Pietro JA, Elko A, Williams EL, Milio L, Velez M. Pregnancies exposed to methadone, methadone and other illicit substances, and poly-drugs without methadone: a comparison of fetal neurobehaviors and infant outcomes. Drug Alcohol Depend. 2012 May 1;122(3):213-9. doi: 10.1016/j.drugalcdep.2011.10.003. Epub 2011 Oct 29.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 1490
- R01DA019934 (Subvention/contrat des NIH des États-Unis)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Maternal fetal monitoring
-
Centre d'Investigation Clinique et Technologique...ComplétéMaladie neuromusculaire | Ventilation mécanique domestiqueFrance
-
Universitätsmedizin MannheimComplétéImmuno-monitoringAllemagne
-
Sun Yat-sen UniversityHangzhou Repugene Technology Co., Ltd.RecrutementCancer du poumon non à petites cellulesChine
-
Azienda Ospedaliero-Universitaria di ParmaRegione Emilia-RomagnaComplétéDiabète sucré, type 1Italie
-
Sun Yat-sen UniversityComplété
-
Yale UniversityComplété
-
The Hong Kong Polytechnic UniversityComplétéAppareil inefficaceHong Kong
-
University College CorkOsypka Medical, Berlin, GermanyRésiliéHémorragie intraventriculaire | Instabilité hémodynamique | Hypotension et choc | Hypoperfusion | Fonction cardiaque | Transition circulatoireIrlande
-
Lille Catholic UniversityInconnueLa dépression | Sclérose en plaquesFrance
-
Singapore General HospitalKK Women's and Children's Hospital; SingHealth PolyclinicsComplété